Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Ophthalmology

Saving Your Sight: Standard of Care Treatment

At a Glance

AAION is an emergency caused by giant cell arteritis. High-dose steroids, often given through a vein first and then as prednisone pills, are started promptly to protect the other eye; vision already lost is usually permanent.

If your doctors suspect Arteritic Anterior Ischemic Optic Neuropathy (AAION), you will be started on high-dose medication immediately—often before any tests are even finished [1][2]. The goal of this rapid intervention is not necessarily to “fix” the vision that has already been lost, but to save the vision you have left [3][4].

The Acute Treatment Goal: Protection

The most critical thing to understand about AAION is that the vision loss from the initial event is usually permanent [5][1]. Because the optic nerve has been starved of blood and oxygen, the tissue is damaged, and while outcomes vary, the loss is usually severe and permanent [5].

However, Giant Cell Arteritis (GCA) is a body-wide disease. Without immediate treatment, there is a very high risk that ongoing GCA can cause ischemic injury in the other eye, often within just a few days [3][2]. High-dose steroids are used to “cool down” the inflamed arteries as quickly as possible to reduce this risk [2][6].

Standard “Pulse” Therapy

For vision-threatening cases, doctors often use a treatment called pulse therapy [1][4]. This typically involves:

  1. Intravenous (IV) Steroids: You may be admitted to the hospital to receive methylprednisolone (often 500 to 1,000 mg per day) through an IV for about 3 days [1][3].
  2. Transition to Oral Medication: After the IV pulses, you will be switched to high-dose oral prednisone (often 60 mg to 80 mg daily) [7][1].

While IV steroids are commonly considered for saving the second eye, high-dose oral steroids are also appropriate in some cases depending on the clinical situation and local protocol [5]. Even after treatment starts, the first 48 hours are the most critical; you must report any new visual “flickers” or dimming in either eye to your medical team instantly [3].

Steroid Safety Rules

Long-term steroid use helps control GCA, but requires strict safety habits:

  • Medication Safety: Never stop abruptly or change your dose without medical advice. Stopping suddenly can cause adrenal crisis [8].
  • Sick day rules: Ask your doctor what to do if you are vomiting and cannot take your pills.

Steroid-Sparing Treatments

Because the inflammation in GCA can last for months or even years, you may need to take steroids for a long time [8]. To avoid the side effects of long-term steroid use (such as bone thinning or high blood sugar), doctors often add steroid-sparing agents [9][10].

  • Tocilizumab (Actemra): This is a modern biological medication that blocks the IL-6 receptor pathway [9]. In major clinical trials, patients taking tocilizumab were much more likely to stay in remission and were able to take significantly lower total doses of steroids [9]. It requires careful screening and monitoring for infection, blood counts, and liver abnormalities, and can make CRP or fever less reliable.
    • Crucial Note: Tocilizumab is not a substitute for emergency steroids in the first few days of AAION [1]. It is used as an adjunct to help you taper off steroids safely [11].
  • Methotrexate: This is an older, well-studied medication that can also help reduce the amount of steroids you need [10]. It is often used if tocilizumab is not an option for you [12].

Why Immediate Action Matters

Every hour counts. In a study of patients who lost vision in their first eye, the median time for the second eye to be affected was only 2 days [3]. This is why your medical team will move with such urgency [6]. Starting treatment at the first sign of clinical suspicion—even if the biopsy hasn’t happened yet—is the standard of care to protect your remaining sight [1][2].

Common questions in this guide

Can treatment restore vision that AAION has already taken away?
Usually not. Vision loss from the initial AAION event is generally permanent because the optic nerve was deprived of blood and oxygen. The urgent purpose of treatment is to reduce the chance that giant cell arteritis damages the other eye.
Why are steroids started before my test or biopsy results are complete?
AAION is usually linked to giant cell arteritis, which can threaten the other eye within days. Doctors start high-dose steroids when clinical suspicion is strong because delaying treatment can increase the risk of further vision loss. Testing or biopsy can often be completed after treatment begins.
What does pulse steroid treatment for AAION involve?
Vision-threatening AAION may be treated in the hospital with intravenous methylprednisolone, often 500 to 1,000 mg daily for about three days, followed by high-dose prednisone pills, often 60 to 80 mg daily. The exact regimen depends on your clinical situation and local treatment protocol.
Can tocilizumab replace emergency steroids for AAION?
No. Tocilizumab is an add-on treatment for giant cell arteritis that may help reduce the need for long-term steroids after the emergency phase. It does not replace high-dose steroids during the first days of vision-threatening AAION.
What should I do if my other eye starts flickering or dimming?
Tell your medical team immediately about any new flickering, dimming, or other change in the other eye, including at night. These symptoms may signal ongoing risk to the optic nerve and require urgent assessment.
Why should I avoid stopping prednisone suddenly?
Do not stop or change long-term steroid treatment without medical advice because sudden withdrawal can cause adrenal crisis, a dangerous shortage of steroid hormone. Ask your clinician for a tapering plan and for instructions if vomiting prevents you from taking your pills.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my vision loss, should I be receiving intravenous 'pulse' steroids in the hospital, and for how many days?
  2. 2.What is the plan to transition from IV steroids to oral medication, and how high will my oral dose be?
  3. 3.Since steroids can cause side effects like high blood sugar or bone loss, what is your plan for monitoring and protecting me during long-term treatment?
  4. 4.When can we discuss adding a steroid-sparing agent like tocilizumab to help reduce my total steroid dose?
  5. 5.If I notice any new flickering or dimming in my other eye tonight, how exactly should I contact the team?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Giant Cell Arteritis: Updates and Controversies.

    Yu E, Chang JR

    Frontiers in ophthalmology 2022; (2()):848861 doi:10.3389/fopht.2022.848861.

    PMID: 38983551
  2. 2

    Giant Cell Arteritis.

    Ness T, Nölle B

    Klinische Monatsblatter fur Augenheilkunde 2024; (241(5)):644-652 doi:10.1055/a-2252-3371.

    PMID: 38593832
  3. 3

    Vision loss in giant cell arteritis: case-based review.

    Kokloni IN, Aligianni SI, Makri O, Daoussis D

    Rheumatology international 2022; (42(10)):1855-1862 doi:10.1007/s00296-022-05160-x.

    PMID: 35727336
  4. 4

    Giant cell arteritis: a closer look at its ophthalmological manifestations.

    Pinto Ferreira NG, Menezes Falcão L, Alves AT, Campos F

    BMJ case reports 2015; (2015()).

    PMID: 26416775
  5. 5

    Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study.

    Dumont A, Lecannuet A, Boutemy J, et al.

    Seminars in arthritis and rheumatism 2020; (50(2)):335-341 doi:10.1016/j.semarthrit.2019.09.008.

    PMID: 32192630
  6. 6

    Biopsy vs imaging in the diagnosis of giant cell arteritis. Viewpoint 1: in favour of imaging.

    Schmidt WA

    Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i71-i73 doi:10.1093/rheumatology/keae487.

    PMID: 40071427
  7. 7

    2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

    Hellmich B, Agueda A, Monti S, et al.

    Annals of the rheumatic diseases 2020; (79(1)):19-30 doi:10.1136/annrheumdis-2019-215672.

    PMID: 31270110
  8. 8

    Neuro-ophthalmic Manifestations of Giant Cell Arteritis: A Review.

    Khoury JA, Albreiki D

    Journal of ophthalmic & vision research 2025; (20()) doi:10.18502/jovr.v20.15248.

    PMID: 40689118
  9. 9

    Trial of Tocilizumab in Giant-Cell Arteritis.

    Stone JH, Tuckwell K, Dimonaco S, et al.

    The New England journal of medicine 2017; (377(4)):317-328 doi:10.1056/NEJMoa1613849.

    PMID: 28745999
  10. 10

    Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements.

    Dammacco R, Alessio G, Giancipoli E, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):775-793 doi:10.2147/OPTH.S243203.

    PMID: 32210531
  11. 11

    Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.

    Christ L, Seitz L, Scholz G, et al.

    The Lancet. Rheumatology 2021; (3(9)):e619-e626 doi:10.1016/S2665-9913(21)00152-1.

    PMID: 38287611
  12. 12

    Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies.

    Badla O, Badla BA, Almobayed A, et al.

    Pharmaceuticals (Basel, Switzerland) 2024; (17(10)) doi:10.3390/ph17101281.

    PMID: 39458922

This page explains emergency AAION treatment for education and does not replace medical advice. Contact your ophthalmology or rheumatology team urgently about vision changes, steroid doses, and treatment decisions.

Get notified when new evidence is published on arteritic anterior ischemic optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.